We’ve secured funding to initiate a non-human primate study, a milestone reached by fewer than 1% of early-stage biotech startups. The study will evaluate our vaccine in geriatric diabetic primates and generate data across atherosclerosis reversal, pulmonary hypertension, and pulmonary fibrosis. The company has completed the NSF I-Corps Program at the University of New Mexico, the Innosphere Ventures incubator, the Nucleate Activator program, and the Founder Institute accelerator, providing venture validation and commercialization support. Our founding team includes scientific and business advisors with deep domain expertise, multiple successful exits, and extensive experience operating in regulated biomedical environments.
This is where a company's traction statement would be visible. As you are not logged in, you cannot see it. When you become an advisor you'll be able to view the traction.
Clinical cardiologists with experience in cardiovascular clinical trials, particularly in atherosclerosis, cardiometabolic disease, or pulmonary hypertension. We’re also interested in advisors with expertise in FDA regulatory strategy for vaccines and biologics, biotech fundraising and venture partnerships, and strategic pharma collaborations in cardiovascular or aging-related diseases.
This is where you can find what a company would like mentoring on. The field will become available when you are onboarded.
